Merck (NYSE:MRK) and Avillion inked a clinical co-development deal today for Merck’s anti IL-17 A/F Nanobody therapy for plaque psoriasis. The financial terms of the deal were not disclosed.
The investigational treatment underwent Phase I development and the group plans to initiate Phase II trials this year. According to the terms of the agreement, Avillion is responsible for bringing the nanobody treatment from Phase II to Phase III and financing the clinical program through to regulatory submission.
Get the full story at our sister site, Drug Delivery Business News.
The post Merck, Avillion ink development deal for nanobody psoriasis treatment appeared first on MassDevice.
from MassDevice http://ift.tt/2om9U0d
Cap comentari:
Publica un comentari a l'entrada